Duality Biotherapeutics (映恩生物) Trading Update
Duality Biotherapeutics raises $194m in global offering will list on Hong Kong Stock Exchange on April 14th. We provide an update before its...
461 Views
Duality Biotherapeutics (映恩生物) Pre-IPO: Valuation and the Trap
China's Duality Biotherapeutics aims to raise $250m in Hong Kong IPO. We provide our valuation on its core products DB-1303, DB-1311, and DB-1305...
610 Views
Wuxi XDC Placement - Following Biologics Playbook, past Deals Have Been Mixed
WuXi AppTec (2359 HK) aims to raise around US$250m via selling around 3.5% stake in WuXi XDC Cayman (2268 HK). In this note, we talk about the deal...
454 Views
Innovent Biologics Inc (1801 HK): 2024 Product Sales Jump 44% and Loss Narrows; Momentum to Continue
Innovent Biologics reports impressive 2024 results with revenue up 52% and net loss narrowing by 91%. The company has set an ambitious growth...
482 Views
Pre-IPO Duality Biotherapeutics (PHIP Updates) - Some Points Worth the Attention
DB-1303 face challenges in commercialization.The priority for DB-1311 is to verify the druggability. Duality’s pre-IPO valuation isn't...
482 Views